Answers are grounded in this paper and cite their sources.
RATIONALE: Chemoradiotherapy (CRT) is the primary treatment for locally advanced cervical cancer (LACC). However, CRT is associated with high toxicity, and access to radiotherapy infrastructure remains limited or unavailable in some settings globally. Neoadjuvant chemotherapy (NACT) followed by radical surgery has therefore been proposed as an alternative to CRT, but the evidence regarding its efficacy and toxicity compared to CRT remains unclear. OBJECTIVES: To compare NACT followed by radical surgery versus CRT for LACC. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, and ClinicalTrials.gov up to 20 May 2026, with no date or language restrictions. We also searched the reference lists of included studies and contacted experts in the field. ELIGIBILITY CRITERIA: We included randomised controlled trials (RCTs) in women with LACC (FIGO 2018 stage IB3/IIA2/IIB/IIIA-C/IVA) comparing NACT followed by radical surgery to CRT. We excluded non-randomised studies. OUTCOMES: Our critical outcomes were overall survival, disease-free survival, and progression-free survival. Important outcomes included recurrence, acute and late toxicity, and quality of life. RISK OF BIAS: We assessed risk of bias in the included studies using Cochrane's RoB 1 tool. SYNTHESIS METHODS: We performed a random-effects meta-analysis using the inverse-variance method. We assessed the certainty of evidence using the GRADE approach. INCLUDED STUDIES: Three RCTs (from four reports), with a total of 1326 women, reported on the outcomes of interest and were included in the meta-analysis. RESULTS: NACT + radical surgery may result in little to no difference in five-year overall survival compared to CRT (hazard ratio (HR) 1.11, 95% confidence interval (CI) 0.90 to 1.36; I² = 0%; 2 studies, 1259 participants; low-certainty evidence). The evidence is very uncertain for five-year disease-free survival (HR 1.28, 95% CI 0.97 to 1.69; 1 study, 635 participants; very low-certainty evidence) and five-year progression-free survival (HR 1.37, 95% CI 1.07 to 1.75; 1 study, 626 participants; very low-certainty evidence). NACT + radical surgery probably increases grade ≥ 3 acute toxicity (risk ratio (RR) 1.82, 95% CI 1.45 to 2.29; I² = 0%; 2 studies, 1224 participants; moderate-certainty evidence). The evidence is very uncertain for grade ≥ 3 late toxicity (RR 0.71, 95% CI 0.50 to 1.01; 1 study, 591 participants; very low-certainty evidence). NACT + radical surgery may result in little to no difference in quality of life after 24 months compared to CRT (mean difference 0.48, 95% CI -4.35 to 5.31; I² = 0%; 2 studies, 239 participants; low-certainty evidence). The certainty of evidence ranged from very low to moderate, downgraded primarily due to risk of bias, indirectness, and imprecision. AUTHORS' CONCLUSIONS: The current evidence does not support NACT followed by radical surgery as an alternative to CRT for LACC. While five-year overall survival may be comparable between treatments, the evidence is very uncertain for disease-free and progression-free survival, while severe acute toxicity is probably increased. Quality of life appears similar between treatments. The evidence is very uncertain about the effect on severe late toxicity, given the limited evidence base, older radiotherapy techniques used, and high cross-over rates in the included studies. CRT remains the standard of care where high-quality radiotherapy is available; where it is not, the evidence remains insufficient to recommend NACT followed by radical surgery as an alternative. FUNDING: No external funding was received for this review. REGISTRATION: doi: 10.1002/14651858.CD014684.
No takes yet. Share an insight, caveat, or question.
Athanasiou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: